




About the Cover

December 1, 2016; Volume 57, Issue 12

Cover image



^{225}Ac -PSMA-617 has shown high potential to benefit patients with metastatic castration-resistant prostate cancer who are in a clinically critical situation. See page 1941.

[^ Back to top](#)

[← Previous](#)

[Next →](#)

In this issue

**UH & EURATOM Ex. 2025-001
Fusion v. Universität Heidelberg, et al.
IPR2023-00551**



Journal of Nuclear Medicine

Vol. 57, Issue 12

December 1, 2016

[Table of Contents](#)

[Table of Contents \(PDF\)](#)

[About the Cover](#)

[Index by author](#)

Issue highlights

[Clinically Approved Nanoparticle Imaging Agents](#)

[In Vivo Imaging of Human \$^{11}\text{C}\$ -Metformin in Peripheral Organs: Dosimetry, Biodistribution, and Kinetic Analyses](#)

[Quantification of Task-Specific Glucose Metabolism with Constant Infusion of \$^{18}\text{F}\$ -FDG](#)

[Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions](#)



 [Sign up for alerts](#)



Most Cited	Most Read
Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling	
Initial Clinical Experience with ⁹⁰ Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients	
⁶⁸ Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the ⁶⁸ Ga-FAPI PET Prospective Observational Trial	
Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial	
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷ Lu-FAP-2286: First-in-Humans Results	
UH & EURATOM Ex. 2025-003 Fusion v. Universität Heidelberg, et al. IPR2023-00551	

More...



S NM
M I

© 2023 Journal of Nuclear Medicine

UH & EURATOM Ex. 2025-004
Fusion v. Universität Heidelberg, et al.
IPR2023-00551